Sunday, October 23, 2016

Hester Bio - Notes from the Annual Report - 2016

• Cumulative production capacity of 6 bn doses once the Nepal capacity goes online
• 2015-16 performance was achieved despite a 6-month trough in India's poultry sector that affected the sector for 3 quarters. The trough was the result of high feed cost and low realization of poultry output of meat and eggs. This resulted in a lower replacement of chicks.
• Started trial production of two batches in its Nepal plant and submitted these to regulatory authorities in 2 African countries
• HBS has decided to make a strategic shift to health products over dependence on poultry products
• Focus on exports to de-risk company from exclusively depending on domestic market
• Poultry Vaccines Segment: Introduced two Poultry Vaccines namely the Salmonella Live Vaccine and the Inclusion Body Hepatitis Vaccine
• Large Animal Vaccines: started manufacturing and marketing of large animal vaccines. Currently, manufactures PPR and goat pox vaccine. The Indian plant at Mehsana produces the PPR Live vaccine strain meant for India (sungri strain); the Nigerian strain will be made in the Nepal plant for export markets
• Brucella abortus S19 vaccine will be commercialized this year
• Large Animal health Products Segment: Comprises of medicinal products, feed additives & disinfectants. HBS does not manufacture products themselves. The outlook for growth is robust and can outperform the other divisions in the near future.

Sunday, October 9, 2016

Notes from Annual Report 2016: Poly Medicure

  • Revenue was 402.86 cr vs 381.9 cr in FY15
  • Net profit was 47.30 cr vs 61.01 cr (including 19.57 cr of exceptional items) in FY15
  • EPS was 10.72 vs 13.83 in FY15

  • PML is starting a new R&D center with an investment of 12.5cr which is to be operational by Q3 2016
  • New green field project at IMT Faridabad which is to be operational by Q3 2017 on an investment of 60cr
  • PML to focus on new market opportunities in Oncology, Nephrology & Respiratory Care segments
  • Product expansion is in process for Infusion therapy and Blood Management
  • PML is planning to launch 8-10 new products in FY17
  • PML is now exporting products to 95 countries
  • PML is now present in 3000 key hospitals in India and plans to expand to 5000 hospitals in next 2 years
  • Expanded the sales and marketing team with 80 new team members
  • The Indian medical device market is the top 20 in the world and 4th in Asia after Japan, China & South Korea
  • The medical devide sector was valued at USD 6.3 in 2013 and is expected to grow to USD25-30 by 2025
  • PML is the leading exporter of infusion therapy, blood management, gastroenterology, surgery and wound drainage,
    anesthesia and urology products
  • Over 65% of revenues come from exports
  • PML has 144 product and process patents globally; filed for additional 394 patents in India and worlwide


Disclaimer: I am not an investment analyst. Stocks discussed in the blog should not be construed as buy / sell recommendations. This blog is a chronicle of my actions and thoughts in the markets. This blog is NOT for providing investment tips or advice. Please consult an accredited financial advisor before investing yourself.